Pulmonary Drug Delivery Systems Market Outlook:
Pulmonary Drug Delivery Systems Market size was valued at USD 59.33 Billion in 2025 and is likely to cross USD 97.57 Billion by 2035, expanding at more than 5.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of pulmonary drug delivery systems is assessed at USD 62.05 Billion.
The growth of the market can be attributed to the surge in cases of asthma worldwide, coupled with increasing instances of pulmonary disorders, and growing funding from government and private organizations for better therapy management across the globe. People are now becoming more aware of these diseases and disorders, which is further expected to fuel the market over the forecast period. According to the World Health Organization, an estimated 262 million people suffered from asthma around the world in 2019 and it caused 455 000 deaths.
Global pulmonary drug delivery systems market trends such as, technological advancements in the pharmaceutical industry, increasing consumption of tobacco and smoking, backed by exposure to air pollution, along with development in drug delivery systems owing to growing health care spending are anticipated to fuel market growth during the forecast period. For instance, in February 2022, AptarGroup, Inc. launched HeroTracker Sense, a smart connected respiratory health device, that transforms a standard metered dose inhaler (pMDI) into a digital respiratory health tool. Hence, all these factors are anticipated to boost the market’s growth over the forecast period.
